This review is published by the SMC Research Desk for informational and educational purposes only. It does not constitute medical advice. WGCP ADDY Focus is a dietary supplement — not a prescription medication — and has not been evaluated by the FDA to diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare provider before starting any supplement, particularly if you take prescription medications, have cardiovascular conditions, or are sensitive to stimulants.
What SMC Found After Reviewing WGCP ADDY Focus
WGCP ADDY Focus occupies an unusual position in the nootropic supplement market. Most products in this category cite ingredient research loosely, list clinical citations that don't actually study the finished product, and hope readers don't look closely. WGCP ADDY at least partially breaks that pattern: the primary active ingredient — Whole Green Coffee Powder (WGCP) — was the subject of a published double-blind study conducted at the Cleveland Clinic. That study is real, its methodology is reviewable, and its results tell a more specific story than the marketing copy does.
This review examines what the Cleveland Clinic study actually found, what it didn't find, how the verified label compares to the marketing copy, and who this product is and isn't suited for. The SMC Research Desk does not inflate findings or suppress limitations. Both are present here.
WGCP ADDY Focus is manufactured and sold by Primal Health LP, headquartered in Plano, Texas. It is sold as a subscription product at $57.99 per 30-day supply (60 capsules), with a 50% introductory discount available at $28.99 for the first month. Subsequent subscription billing occurs at the standard rate. Cancellation and subscription management are available online at members.primallabs.com or by phone at 877-300-7849.
The Verified Supplement Facts Panel
Every SMC review opens with the verified label. The marketing copy for WGCP ADDY references the 1,602mg proprietary blend. The Supplement Facts panel confirms this and specifies the three ingredients: WGCP (Whole Green Coffee Powder), Amla (Sanskrit Amalaki Powder, standardized from Emblica officinalis), and Brahmi (Bacopa monnieri Powder).
The panel does not break out individual weights for each ingredient within the proprietary blend. All three are included in the stated 1,602mg total. The only other declared ingredient is vegetable cellulose (capsule shell). The label also carries a mandatory warning: each capsule contains 80mg of naturally occurring plant-based caffeine from raw Coffea canephora. A standard 2-capsule serving therefore delivers 160mg of caffeine — roughly equivalent to one and a half standard cups of drip coffee. The label advises limiting other stimulants and caffeinated beverages while taking this product.
Additional label warnings: not for persons under 18 except under physician supervision, contraindicated during pregnancy and breastfeeding, and caution is advised for anyone taking heart-related prescription medications. These are material disclosures, not fine print. Anyone managing a cardiovascular condition or taking heart medications should have a physician conversation before starting this supplement.
What the Cleveland Clinic Study Actually Found
The study — Manos, Sidol, Monaco, and Frazier, published in Clinical Medicine Insights: Psychiatry (2014) — was a double-blind, withdrawal-design study conducted at Cleveland Clinic's Center for Pediatric Behavioral Health. It was funded by an unrestricted grant from ADDY Products LLC. That funding relationship is disclosed in the study and is relevant context for interpreting the results.
The study enrolled 14 neurotypical adults aged 18–25, none of whom had a diagnosis of ADHD or other qualifying psychiatric conditions. Participants served as their own controls across three conditions: placebo (corn starch), low-dose WGCP (889.9mg, approximately 2 capsules of the commercial product), and moderate-dose WGCP (1,334.4mg, approximately 3 capsules). Cognitive function was assessed using the CANTAB ADHD battery — a validated, computerized neuropsychological test battery — measuring sustained attention, spatial working memory, and response inhibition.
Results at moderate dose: sustained attention improved significantly (p=0.022) and spatial working memory errors decreased significantly (p=0.001). Results at low dose: sustained attention and working memory both worsened compared to placebo. Response inhibition showed no significant change at any dose. No adverse side effects were reported at any dose. Fifty percent of participants subjectively reported an improved sense of well-being during the moderate-dose condition.
The study's primary limitation, acknowledged by the authors themselves, is sample size: 14 subjects. The authors specifically call for larger randomized controlled trials. The study's design — a small-N withdrawal protocol — is a legitimate and recognized methodology for early-stage compound research, but it does not constitute the same level of evidence as a large-scale RCT. The Cleveland Clinic study is a meaningful signal, not a definitive proof of efficacy at scale.
What this means for a prospective buyer: the research provides a credible mechanistic basis for expecting some cognitive support from WGCP at the 1,334mg dose range. It does not guarantee individual results, and the two-capsule serving in the commercial product delivers 801mg of the full 1,602mg blend — not 1,334mg of pure WGCP, since that total is shared across WGCP, Amla, and Brahmi. Because individual ingredient weights within the blend are not disclosed, it is not possible to confirm from the label alone that the commercial serving delivers WGCP at the exact moderate-dose studied.
Ingredient-Level Analysis: WGCP, Brahmi, and Amla
WGCP (Whole Green Coffee Powder) is the formulation's central compound. Unlike green coffee extract, which isolates chlorogenic acids and removes other constituents, WGCP is processed from whole green coffee beans using a fine-grain pulverizing method that preserves fiber, chlorogenic acid, micronutrients, and naturally occurring caffeine in their native proportions. The Cleveland Clinic researchers specifically noted that the slow-release delivery of caffeine and chlorogenic acid via WGCP's fiber matrix may explain the absence of typical stimulant side effects — jitteriness, post-dose crash, and tolerance accumulation — observed in standard caffeine extract products. The WGCP ingredient has also received STRONGSCIENCE certification from Global Clinicals, a third-party natural products CRO that reviews dietary supplements for dose alignment with current ingredient safety monographs.
Brahmi (Bacopa monnieri) is one of the most extensively researched cognitive-support botanicals in the nootropic category. A meta-analysis published in the Journal of Ethnopharmacology (Kongkeaw et al., 2014), covering 9 randomized controlled trials, found that Bacopa monnieri significantly improved cognition, with the strongest effects on speed of attention and delayed memory recall. A separate randomized controlled trial (Stough et al., Psychopharmacology, 2001) found significant improvements in visual information processing, learning rate, and memory consolidation after 12 weeks of use. The Bacopa literature consistently shows that cognitive effects build over weeks of continued use — they are not acutely immediate in the same manner as caffeine. This is relevant context for evaluating WGCP ADDY: the WGCP component may provide acute support, while the Brahmi component may require consistent daily use over 4–12 weeks to exhibit its full contribution.
Amla (Emblica officinalis) is a fruit widely used in Ayurvedic medicine and is one of the most potent natural antioxidant sources documented in the botanical literature. A study published in Physiology and Behavior (Vasudevan and Parle, 2007) found that Emblica officinalis extract improved learning and memory in animal models, with the researchers attributing the effect to the fruit's antioxidant reduction of oxidative stress in neural tissue. Human trial data specifically on cognitive outcomes from Amla supplementation is more limited than for Bacopa. The ingredient's primary documented contribution is antioxidant and neuroprotective rather than acute cognitive stimulation.
Pricing, Subscription, and Refund Terms
The product is available exclusively through Primal Health LP's direct-to-consumer channel. The standard price is $57.99 for a 30-day supply (60 capsules, 2-capsule daily serving). An introductory subscription offer reduces the first month to $28.99 — approximately $0.97 per day. Subsequent months bill at the standard subscription rate. U.S. shipping is included at no additional cost.
Cancellation can be executed online at members.primallabs.com or by phone at 877-300-7849. The product page states a 30-day satisfaction window; the guarantee copy elsewhere on the same page references 60 days. Customers should confirm current refund terms at checkout, as the policy language contains an internal inconsistency in the version reviewed. A small return processing fee applies per the stated terms.
Subscription auto-ships every 30 days. The company specifically frames the subscription structure around consistent daily use — the Bacopa component in particular is supported by research showing that benefits accumulate with continued use rather than appearing after a single dose. This is a scientifically sound rationale for a subscription model, though readers should not interpret it as a cancellation barrier. The cancellation process is stated as penalty-free and available online or by phone.
Who WGCP ADDY Is and Isn't Suited For
This product is plausibly suited for: adults seeking non-prescription focus support who have tried standard caffeine products and found the side effect profile — jitteriness, crash, tolerance accumulation — unsatisfactory. The WGCP delivery mechanism provides a rationale for reduced crash and jitter relative to isolated caffeine. The Brahmi component provides a rationale for cognitive accumulation over consistent use. The 160mg caffeine per serving is meaningful and should not be ignored, but its delivery through the whole-bean fiber matrix appears to produce a more attenuated stimulant profile than equivalent doses of caffeine extract.
This product is not suited for: individuals under 18 except under physician supervision, anyone who is pregnant or breastfeeding, anyone taking heart-related prescription medications without physician clearance, anyone sensitive to stimulants, or anyone managing a cardiovascular condition without having consulted their physician. The 160mg per serving caffeine content is also a practical consideration for anyone who is caffeine-sensitive or who consumes substantial caffeine through other sources during the day.
WGCP ADDY makes no ADHD treatment claims — the manufacturer explicitly states it opted not to pursue drug classification. The supplement should not be used as a substitute for evaluation or treatment of a diagnosed attention disorder. Any reader managing ADHD or considering adjustments to existing prescription treatments should work with their prescribing physician before incorporating this or any supplement into their regimen.
SMC Verdict
WGCP ADDY Focus is a better-documented nootropic than most of its competition. The primary active ingredient has a published, peer-reviewed study from a credentialed institution behind it. The study is modest in scale and was industry-funded — both of which the authors disclosed — but its double-blind, withdrawal design is methodologically sound for a preliminary investigation, and the cognitive outcomes at moderate dose were statistically significant. The Brahmi component is supported by a meaningful body of independent clinical literature. The Amla component contributes antioxidant properties with more limited direct cognitive evidence.
The limitations are real: the proprietary blend does not disclose individual ingredient weights, which makes it impossible to confirm from the label that the two-capsule serving delivers WGCP at the specific dose studied. The refund policy language contains an inconsistency between 30 and 60 days that should be confirmed at the point of purchase. And any assessment of whether this product is worth the ongoing subscription cost ultimately depends on individual response — something no review can determine in advance.
For more on what the research says about each ingredient in this formula, see WGCP Explained: The Ingredient Behind ADDY Focus. For a comparison of how WGCP ADDY stacks up against other nootropic supplements in this category, see WGCP ADDY vs Other Nootropics: A Direct Comparison. For a complete safety profile including interactions and contraindications, see WGCP ADDY Side Effects, Safety and Who Should Avoid It. For a direct breakdown of whether the evidence supports the product's central claims, see Does WGCP ADDY Work? Breaking Down the Evidence.
Frequently Asked Questions
What is WGCP ADDY Focus?
WGCP ADDY Focus is a dietary supplement produced by Primal Health LP that combines a 1,602mg proprietary blend of Whole Green Coffee Powder (WGCP), Amla (Emblica officinalis), and Brahmi (Bacopa monnieri) in a 2-capsule daily serving. It is sold as a non-prescription focus support supplement.
Was WGCP ADDY actually tested by the Cleveland Clinic?
Yes. A double-blind, withdrawal-design study conducted at the Cleveland Clinic Center for Pediatric Behavioral Health tested WGCP — the primary active ingredient — on 14 neurotypical adults aged 18–25. The study was funded by an unrestricted grant from ADDY Products LLC. Moderate-dose WGCP (1,334mg) significantly improved sustained attention and spatial working memory. Low-dose WGCP (890mg) showed a negative effect on the same measures. No adverse side effects were reported.
How much caffeine is in WGCP ADDY?
The product label discloses 80mg of naturally occurring plant-based caffeine per capsule from raw Coffea canephora. A standard 2-capsule serving delivers 160mg of caffeine. The label advises limiting other stimulants and caffeinated beverages while taking this product.
What is the refund policy for WGCP ADDY?
Primal Health LP offers a money-back guarantee with a contact window stated at 30 days on the product page and 60 days in the guarantee copy. A small return processing fee applies per the stated terms. Cancellations and subscription management are handled at members.primallabs.com or by calling 877-300-7849.
Does WGCP ADDY work for ADHD?
WGCP ADDY is a dietary supplement and is not approved to diagnose, treat, or cure ADHD or any medical condition. The Cleveland Clinic study was conducted on neurotypical adults without diagnosed ADHD. The manufacturer explicitly states it opted not to pursue drug classification. Anyone with a diagnosed attention disorder should consult a qualified healthcare provider before use.